Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg

Abstract

Purpose:To evaluate the intraocular pressure (IOP) reducing effect of a fixed combination of 0.005% latanoprost and 0.5% timolol in patients with an IOP of 30 mmHg or higher.Design:Prospective, randomized clinical trial.Participants: Twenty-eight patients.Methods:Patients had received no prior medical glaucoma treatment. Routine ophthalmic examinations and visual field tests were performed before and after treatment for each patient.Results:Mean IOP was 32.28 ± 0.92 mmHg before treatment. Mean IOP levels were 18.75 ± 0.68 for the first day, 17.96 ± 0.90 for the first week and 17.64 ± 0.66 for the first month after treatment.Conclusion:A fixed combination of latanoprost 0.005% and timolol 0.5% is effective in significantly reducing IOP in glaucoma patients with an IOP greater than 30 mmHg.

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study

“…A small, uncontrolled 2009 study assessed the use of latanoprost/timolol fixed combination (LTFC) in 28 previously untreated glaucoma patients with IOP ≥30 mmHg (21 POAG, six pseudoexfoliative glaucoma, and one pigmentary glaucoma) 14. At 1 month, IOP was reduced by 14.6 mmHg, but from a higher baseline IOP than in this study and over a shorter time period.…”